Poly(hydrophobic amino acid) Conjugates for the Delivery of Multiepitope Vaccine against Group A Streptococcus

Author(s):  
Armira Azuar ◽  
Mohini A. Shibu ◽  
Nomin Adilbish ◽  
Nirmal Marasini ◽  
Hong Hung ◽  
...  
2015 ◽  
Vol 185 (2) ◽  
pp. 462-471 ◽  
Author(s):  
Misu Sanson ◽  
Brian E. O'Neill ◽  
Priyanka Kachroo ◽  
Jeff R. Anderson ◽  
Anthony R. Flores ◽  
...  

2011 ◽  
Vol 18 (4) ◽  
pp. 552-558 ◽  
Author(s):  
Cuiqing Ma ◽  
Yiyang Guo ◽  
Haiyan Gu ◽  
Ling Zhang ◽  
Hainan Liu ◽  
...  

ABSTRACTSome microbial pathogens utilize human complement regulatory proteins, such as factor H (FH) and factor H-like protein 1 (FHL-1), for immune evasion. FbaA is an FHL-1 and FH binding protein expressed on the surface of group A streptococcus (GAS), a common agent of pharyngeal, skin, and soft tissue infections. In this study, we prepared monoclonal antibodies (MAbs) against FbaA, assayed them for specificity, and located their binding domains in FbaA. We found an MAb called FbaA MAb2, which demonstrated the highest affinity to GAS among all of the MAbs. Based on the binding with component peptides, the detected epitope, which was specific for FbaA MAb2, was the amino acid residues 95 to 118 of FbaA; on the other hand, it did not bind with the truncated protein of the internally deleted residues of the segment from 95 to 118 of FbaA. Furthermore, the predominant amino acids specific for FbaA MAb2 screened by phage display epitope library were I, T, P, D, and L, corresponding to the amino acid residues 101, 103, 105, 106, and 110 of FbaA, respectively. The binding location of FbaA with FH and FHL-1 was a 16-amino-acid region corresponding to amino acid residues 97 to 112 of FbaA, which overlapped the FbaA MAb2 binding domain, as confirmed by competitive inhibition enzyme-linked immunosorbent assay and immunofluorescence microscopy. Based on the results of the invasion assay, FbaA MAb2 can inhibit the binding of FH to GAS.


2004 ◽  
Vol 72 (3) ◽  
pp. 1799-1803 ◽  
Author(s):  
Sean D. Reid ◽  
Alison G. Montgomery ◽  
James M. Musser

ABSTRACT We have identified a Crp/Fnr-like transcriptional regulator of Streptococcus pyogenes that when inactivated attenuates virulence. The gene, named srv for streptococcal regulator of virulence, encodes a 240-amino-acid protein with 53% amino acid similarity to PrfA, a transcriptional activator of virulence in Listeria monocytogenes.


2001 ◽  
Vol 69 (2) ◽  
pp. 1215-1220 ◽  
Author(s):  
Brandi Limbago ◽  
Kevin S. McIver ◽  
Vikram Penumalli ◽  
Brian Weinrick ◽  
June R. Scott

ABSTRACT The Mga protein in B514Sm, a Streptococcus pyogenesstrain isolated as a mouse pathogen, contains amino acid substitutions at conserved sites that render the protein defective. Replacement ofmga50 with the functional homolog mga4.1restored full expression of Mga-regulated proteins. Restoration of Mga function did not affect fibrinogen binding, nor did it affect virulence in several mouse models of group A streptococcus infection.


2020 ◽  
pp. 64-70
Author(s):  
Anastasiya Laknitskaya

Currently, one of the priority medical and social problems is the optimization of treatment methods for pyoderma associated with Streptococcus pyogenes — group A streptococcus (GAS). To date, the proportion of pyoderma, the etiological factor of which is Streptococcus pyogenes, is about 6 % of all skin diseases and is in the range from 17.9 to 43.9 % of all dermatoses. Role of the bacterial factor in the development of streptococcal pyoderma is obvious. Traditional treatment complex includes antibacterial drugs selected individually, taking into account the antibiotic sensitivity of pathognomonic bacteria, and it is not always effective. Currently implemented immunocorrection methods often do not take into account specific immunological features of the disease, the individual, and the fact that the skin performs the function of not only a mechanical barrier, but it is also an immunocompetent organ. Such an approach makes it necessary to conduct additional studies clarifying the role of factors of innate and adaptive immunity, intercellular mediators and antioxidant defense system, that allow to optimize the treatment of this pathology.


Sign in / Sign up

Export Citation Format

Share Document